Article
Dynamics of SARS-CoV-2 variants and mutations in Central Sweden between 2023 and 2024 and their potential implications on monoclonal antibodies pemivibart and sipavibart as PrEP in the region.
Infectious diseases (London, England) - 1 Oct 2025
Haars Jonathan, Wallin Frans, Elfving Karin, Jonsson Anna-Karin, Ellström Patrik, Mölling Paula, Lindh Johan, Yin Hong, Sundqvist Martin, Kaden René, Palanisamy Navaneethan, Lennerstrand Johan
Abstract excerpt
BACKGROUND: Monoclonal antibodies (mAbs) are an important option against SARS-CoV-2, especially as pre-exposure prophylaxis (PrEP) for patients with immune system impairment. PrEP mAbs like sipavibart and pemivibart have been approved for limited use in several countries. Certain SARS-CoV-2 variants carry mutations in the spike (S) protein, conferring resistance to these mAbs. OBJECTIVES: We aimed to examine the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.